

Medical Coverage Policy | Esophageal pH Monitoring

EFFECTIVE DATE: 10/15/2015

POLICY LAST UPDATED: 12/16/2020



**Blue Cross
Blue Shield**
of Rhode Island

OVERVIEW

Esophageal pH monitoring using wired or wireless devices can record the pH of the lower esophagus for a period of 1 to several days. These devices may aid in the diagnosis of gastroesophageal reflux disease (GERD) in patients who have an uncertain diagnosis after clinical evaluation and endoscopy.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Prior authorization review is not required.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial

Esophageal pH monitoring using a wireless or catheter-based system may be considered medically necessary in adults and children or adolescents able to report symptoms.

24-hour catheter-based esophageal pH monitoring may be considered medically necessary in infants or children who are unable to report or describe symptoms of reflux.

Catheter-based impedance-pH monitoring may increase positive tests or diagnostic yield, the potentially increased sensitivity may be accompanied by a decrease in specificity and the net effect on patient management and patient outcomes is not certain. There are no studies of clinical utility showing improved outcomes, and the indirect chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology improves health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND

Acid reflux is the cause of heartburn and acid regurgitation esophagitis, which can lead to esophageal stricture. Acid reflux can also cause or contribute to some cases of asthma, posterior laryngitis, chronic cough, dental erosions, chronic hoarseness, pharyngitis, subglottic stenosis or stricture, nocturnal choking, and recurrent pneumonia.

Gastroesophageal reflux disease (GERD) is most commonly diagnosed by clinical evaluation and treated empirically with a trial of medical management. For patients who do not respond appropriately to medications, or who have recurrent chronic symptoms, endoscopy is indicated to confirm the diagnosis and assess the severity of reflux esophagitis. In some patients, endoscopy is nondiagnostic, or results are discordant with the clinical evaluation. In these cases, further diagnostic testing may be of benefit.

Esophageal monitoring is done using a tube with a pH electrode attached to its tip, which is then passed into the esophagus to approximately 5 cm above the upper margin of the lower esophageal sphincter. The electrode is attached to a data recorder worn on a waist belt or shoulder strap. Every instance of acid reflux, as well as its duration and pH, is recorded over a 24-hour period. Wireless pH monitoring is achieved using

endoscopic or manometric guidance to attach the pH measuring capsule to the esophageal mucosa using a clip. The capsule records pH levels for up to 96 hours and transmits them via radiofrequency telemetry to a receiver worn on the patient's belt. Data from the recorder are uploaded to a computer for analysis by a nurse or doctor.

Another technology closely related to pH monitoring is impedance pH monitoring, which incorporates pH monitoring with measurements of impedance, a method of measuring reflux of liquid or gas of any pH. Multiple electrodes are placed along the length of the esophageal catheter. The impedance pattern detected can determine the direction of flow and the substance (liquid or gas). Impedance monitoring is able to identify reflux events in which the liquid is only slightly acidic or nonacidic.

For individuals who have GERD who receive catheter-based pH monitoring, the evidence includes various cross-sectional studies in different populations evaluating test performance. Relevant outcomes include test accuracy and validity, symptoms, and functional outcomes. Positive pH monitoring tests correlate with endoscopically defined GERD and with GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. There are no studies of clinical utility showing improved outcomes, and the indirect chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology improves health outcomes.

For individuals who have GERD who receive wireless pH monitoring, the evidence includes various cross-sectional studies in different populations evaluating test performance and diagnostic yield. Relevant outcomes include test accuracy and validity, symptoms, and functional outcomes. Positive wireless pH monitoring tests correlate with endoscopically defined GERD and with GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. Some studies have shown higher positive test rates with prolonged wireless monitoring compared to catheter-based pH monitoring, but the effect of this finding on patient outcomes is uncertain. There are no studies of clinical utility showing improved outcomes, and the indirect chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology improves health outcomes.

For individuals who have GERD who receive impedance pH testing, the evidence includes various cross-sectional studies in different populations evaluating test performance and diagnostic yield. Relevant outcomes include test accuracy and validity, symptoms, and functional outcomes. Positive impedance pH tests correlate with endoscopically defined GERD and with GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. Some studies have shown higher positive test rates with impedance pH testing compared to pH testing alone, but the effect of this finding on patient outcomes is uncertain. There are no studies of clinical utility showing improved outcomes, and the indirect chain of evidence supporting utility of the test is weak. The evidence is insufficient to determine that the technology improves health outcomes.

Expert clinical opinion has suggested that catheter-based and wireless pH monitoring may aid in the diagnosis of GERD in patients who have an uncertain diagnosis after clinical evaluation and endoscopy. Esophageal pH monitoring is not considered a standard diagnostic test for most patients with GERD, but there is strong clinical support for its use in selected subpopulations for certain indications. Clinical guidelines support pH testing for patients with GERD being considered for surgical intervention. Wireless pH monitoring

REGULATORY STATUS

Esophageal pH electrodes are considered class I devices by the U.S. Food and Drug Administration (FDA) and are exempt from 510(k) requirements. A catheter-free, temporarily implanted device (Bravo™ pH Monitoring System; Medtronic) was cleared for marketing by FDA through the 510(k) process for the purpose of "gastroesophageal pH measurement and monitoring of gastric reflux in adults and children from 4 years of age."

A number of wireless and catheter-based (wired) esophageal pH monitoring devices have been cleared for marketing by FDA through the 510(k) process. Examples include the Bravo pH Monitoring System (Given

Imaging), the Sandhill Scientific PediaTec™ pH Probe (Sandhill Scientific), the ORION II Ambulatory pH Recorder (MMS, Medical Measurement Systems), and the TRIP CIC Catheter (Tonometrics). FDA product code: FFT.

CODING

The following CPT codes are medically necessary when filed with a covered diagnosis:

91034 Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation

91035 Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation

Covered ICD 10 Diagnosis

G47.30-G47.33

J37.0

J45.20-J45.99

J69.0

K21.0-K21.9

P28.0-P28.9

R00.1

R05

R06.81

R06.1

R06.2

The following CPT codes are not medically necessary:

91037 Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation

91038 Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation; prolonged (greater than 1 hour, up to 24 hours)

RELATED POLICIES

None

PUBLISHED

Provider Update, February 2021

Provider Update, February 2020

Provider Update, November/December 2018

Provider Update, January 2018

Provider Update, January 2017

Provider Update, August 2015

REFERENCES¹

1. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology. Jun 1996;110(6):1982-1996. PMID 8964428
2. Blue Cross and Blue Shield Assicaiton Technology Evaluation Center (TEC). Special Report: Wireless pH Monitoring. TEC Assessments. 2006;21(2).
3. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. Apr 2005;3(4):329-334. PMID 15822037
4. Wenner J, Johansson J, Johnsson F, et al. Optimal thresholds and discriminatory power of 48-h wireless esophageal pH monitoring in the diagnosis of GERD. Am J Gastroenterol. Sep 2007;102(9):1862-1869. PMID 17509034
5. Schneider JH, Kramer KM, Konigsrainer A, et al. Ambulatory pH: monitoring with a wireless system. Surg Endosc. Nov 2007;21(11):2076-2080. PMID 17484003

6. Hakanson BS, Berggren P, Granqvist S, et al. Comparison of wireless 48-h (Bravo) versus traditional ambulatory 24-h esophageal pH monitoring. *Scand J Gastroenterol.* 2009;44(3):276-283. PMID 19040176
7. Scarpulla G, Camilleri S, Galante P, et al. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. *Am J Gastroenterol.* Dec 2007;102(12):2642-2647. PMID 17850412
8. Garrean CP, Zhang Q, Gonsalves N, et al. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. *Am J Gastroenterol.* Jul 2008;103(7):1631-1637. PMID 18557714
9. Grigolon A, Consomni D, Bravi I, et al. Diagnostic yield of 96-h wireless pH monitoring and usefulness in patients' management. *Scand J Gastroenterol.* May 2011;46(5):522-530. PMID 21366495
10. Bajbouj M, Becker V, Neuber M, et al. Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. *Digestion.* 2007;76(3-4):223-228. PMID 18174685
11. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. *Am J Gastroenterol.* Mar 2006;101(3):453-459. PMID 16464226
12. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut.* Oct 2006;55(10):1398-1402. PMID 16556669
13. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. *Gastroenterology.* Jun 2001;120(7):1599-1606. PMID 11375942
14. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. *Am J Gastroenterol.* Mar 2007;102(3):668-685. PMID 17335450
15. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* Mar 2013;108(3):308-328; quiz 329. PMID 23419381
16. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology.* Oct 2008;135(4):1383-1391, 1391 e1381-1385. PMID 18789939
17. National Institute for Health and Care Excellence (NICE). Catheterless esophageal pH monitoring [IPG187]. 2006; <https://www.nice.org.uk/Guidance/IPG187>. Accessed October, 2016

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

